Tognetti L, Cinotti E, Fiorani D, et al. - In this investigation, researchers analyzed clinical and dermoscopic characteristics of basal cell carcinomas (BCCs) before, during, and after 72 weeks of vismodegib administration and identified those most indicative of tumor persistence/clearing. At 10 observation times (t0–t9), clinical and dermoscopic images (n = 380 each) of 38 BCCs were acquired. Treatment-emergent adverse events impact the proper administration of vismodegib and thus its efficacy. Overall, the most common reasons for discontinuing treatment are muscle spasms, dysgeusia, alopecia and diarrhea. In terms of morphology, superficial nonpigmented BCCs with an average diameter < 1.2 cm responded best to vismodegib, followed by pigmented BCCs, on the other hand, the worst were pigmented superficial or nodular subtypes and/or with an average diameter of > 1.2 cm.